Tony Abraham, DO, MPA, discusses how the emergence of PSMA-PET imaging has impacted the staging and management of patients with prostate cancer.
Video content above is prompted by the following question:
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.